Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma

The anti-PD-1 antibodies nivolumab and pembrolizumab are active in metastatic melanoma; however, there is limited data on combining anti-PD-1 antibody and radiotherapy (RT). We sought to review clinical outcomes of patients receiving RT and anti-PD-1 therapy. All patients receiving anti-PD-1 antibod...

詳細記述

保存先:
書誌詳細
出版年:Oncoimmunology
主要な著者: Liniker, E., Menzies, A. M., Kong, B. Y., Cooper, A., Ramanujam, S., Lo, S., Kefford, R. F., Fogarty, G. B., Guminski, A., Wang, T. W., Carlino, M. S., Hong, A., Long, G. V.
フォーマット: Artigo
言語:Inglês
出版事項: Taylor & Francis 2016
主題:
Original Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5048757/
https://ncbi.nlm.nih.gov/pubmed/27757312
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1214788
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料